 There are 2 other main medications that have been approved across the world, for example, montelukast which was approved February 2nd, 1996 and pranlukast which was approved March 15th, 2007.There hasn’t just been interest in the CysLT1 receptor, there has also been interest in the CysLT2 receptor which can be found in smooth muscle cells in the airways, as well as inflammatory cells and endothelial cells, which may be a useful target for asthma patients.There have been discoveries of dual CysLT1 and CysLT2 receptor antagonists, for example, Gemilukast which could be a useful therapeutic agent for asthma patients which are non-responsive to montelukast, zafirlukast and pranlukast.